Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | GPR3 | P46089 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248397 | 0.80 | LMNA (0.50) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL14730818 | 0.80 | MAPKAPK2 (0.44) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL22224694 | 0.71 | ALDH1A1 (0.50) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL18347369 | 0.69 | KIF11 (0.38) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL1966306 | 0.67 | NR1H4 (0.40) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL7126450 | 0.67 | ALDH1A1 (0.44) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL14895777 | 0.67 | ALDH1A1 (0.53) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL21549119 | 0.67 | HTR2A (0.42) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL14731462 | 0.65 | LMNA (0.55) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL20368837 | 0.64 | MEN1 (0.39) | MEN1KMT2AHSD17B10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748167-B1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340548-B2 | Substituted pyrazolo[3,4-a]carbazoles as hepatitis C inhibitors | Boehringer Ingehleim International GmbH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340548-B2 | Substituted pyrazolo[3,4-a]carbazoles as hepatitis C inhibitors | Boehringer Ingehleim International GmbH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| WO-2013026163-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026162-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HCCS, C1R, HAVCR2 | MEN1 2061/4885KMT2A 4109/4885HSD17B10 611/4885 |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HAVCR2, CD4, HAX1 | MEN1 3556/4885KMT2A 4476/4885HSD17B10 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.